Stock Research: Dr. Lal PathLabs

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Dr. Lal PathLabs

NSI:LALPATHLAB INE600L01024
45
  • Value
    14
  • Growth
    94
  • Safety
    Safety
    70
  • Combined
    34
  • Sentiment
    56
  • 360° View
    360° View
    45
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The company offers a range of diagnostic services including core testing, patient diagnosis, prevention, monitoring, and treatment of various diseases, with tests such as Pregnancy Test, Full Body Checkups, Covid 19 Test, and more. It operates throughout India. In the last fiscal year, the company had a market cap of $2902 millions, profits of $229 millions, revenue of $288 millions, and 4980 employees.

more

ANALYSIS: With an Obermatt 360° View of 45 (better than 45% compared with alternatives), overall professional sentiment and financial characteristics for the stock Dr. Lal PathLabs are below the industry average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Dr. Lal PathLabs. The consolidated Growth Rank has a good rank of 94, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 94% of competitors in the same industry. The consolidated Safety Rank at 70 means that the company has a financing structure that is safer than 70% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 56, which means that professional investors are more optimistic about the stock than for 56% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 14, meaning that the share price of Dr. Lal PathLabs is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 86% of alternative stocks in the same industry. ...read more

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 9 1 1
Growth
94 53 83 91
Safety
Safety
70 61 50 56
Sentiment
56 13 37 6
360° View
360° View
45 12 27 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
32 29 3 7
Opinions Change
29 28 50 32
Pro Holdings
n/a 53 77 56
Market Pulse
79 24 65 41
Sentiment
56 13 37 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 9 1 1
Growth
94 53 83 91
Safety Safety
70 61 50 56
Combined
34 22 42 46
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
10 11 7 1
Price vs. Earnings (P/E)
20 17 7 1
Price vs. Book (P/B)
7 10 10 1
Dividend Yield
54 42 26 23
Value
14 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
77 65 62 45
Profit Growth
59 52 75 70
Capital Growth
100 32 90 81
Stock Returns
66 65 33 91
Growth
94 53 83 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
69 56 50 72
Refinancing
48 31 27 27
Liquidity
63 63 53 59
Safety Safety
70 61 50 56

Similar Stocks

Discover high‑ranked alternatives to Dr. Lal PathLabs and broaden your portfolio horizons.

SBI Life Insurance

NSI:SBILIFE
Country: India
Industry: Life & Health Insurance
Size: Large
Full Stock Analysis

Fleury

SAO:FLRY3
Country: Brazil
Industry: Health Care Services
Size: Large
Full Stock Analysis

Ramkhamhaeng Hospital

SET:RAM
Country: Thailand
Industry: Health Care Facilities
Size: Medium
Full Stock Analysis

Polycab India

NSI:POLYCAB
Country: India
Industry: Electr. Components & Equipment
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: